The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5142-5148

  Vilchèze, Catherine ^a   Jacobs, William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DIHYDROFOLATE REDUCTASE; FOLIC ACID; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; RIFAMPICIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOSYNTHESIS; COLONY FORMING UNIT; GROWTH INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 84866328705     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00832-12     Document Type: Article

References (25)

1. Bushby SR. 1975. Synergy of trimethoprim-sulfamethoxazole. Can. Med. Assoc. J. 112:63-66.
2. Bushby SR. 1973. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J. Infect. Dis. 128(Suppl):442-462.
3. Cohen-Bacrie S, et al. 2011. Imported extensively drug-resistant Mycobacterium tuberculosis Beijing genotype, Marseilles, France, 2011. Euro Surveill. 16:19846. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId= 19846.
4. Forgacs P, et al. 2009. Tuberculosis and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 53:4789-4793.
5. Hsieh MH, Yu CM, Yu VL, Chow JW. 1993. Synergy assessed by checkerboard. A critical analysis. Diagn. Microbiol. Infect. Dis. 16:343-349. (Pubitemid 23146839)
6. Huang TS, et al. 2012. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J. Antimicrob. Chemother. 67:633-637.
7. Huovinen P, Sundstrom L, Swedberg G, Skold O. 1995. Trimethoprim and sulfonamide resistance. Antimicrob. Agents Chemother. 39:279-289.
8. Ioerger TR, et al. 2009. Genome analysis of multi-and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One 4:e7778. doi:10.1371/journal.pone.0007778.
9. Koser CU, Summers DK, Archer JA. 2010. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (cotrimoxazole) resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:4951-4952.
10. Lehmann J. 1946. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet i:15.
11. Martin A, et al. 2005. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis. 9:901-906. (Pubitemid 41139650)
12. Mitnick C, et al. 2003. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 348:119-128. (Pubitemid 36056718)
13. Müller-Brundaler U, Dingfelder G, Urbanczik R. 1997. Improbability of selection for RIF resistance in Mycobacterium tuberculosis by accidental exposure during short-course therapy with cotrifazid. Chemotherapy 43:451-452. (Pubitemid 27472553)
14. Nagachar N, Ratledge C. 2010. Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS). FEMS Microbiol. Lett. 311:193-199.
15. Ong W, Sievers A, Leslie DE. 2010. Mycobacterium tuberculosis and sulfamethoxazole susceptibility. Antimicrob. Agents Chemother. 54:2748.
16. Rengarajan J, et al. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol. Microbiol. 53:275-282. (Pubitemid 38901397)
17. Schweitzer BI, Dicker AP, Bertino JR. 1990. Dihydrofolate reductase as a therapeutic target. FASEB J. 4:2441-2452.
18. Smilack JD. 1999. Trimethoprim-sulfamethoxazole. Mayo Clin. Proc. 74:730-734. (Pubitemid 29321291)
19. Suling WJ, et al. 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 42:811-815. (Pubitemid 29008085)
20. Vilchèze C, et al. 2011. Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob. Agents Chemother. 55:3889-3898.
21. Vilchèze C, et al. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12:1027-1029. (Pubitemid 44353383)
22. Wang F, et al. 2010. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob. Agents Chemother. 54:3776-3782.
23. Wayne LG, Hayes LG. 1996. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64:2062-2069. (Pubitemid 26165667)
24. White EL, Ross LJ, Cunningham A, Escuyer V. 2004. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase. FEMS Microbiol. Lett. 232:101-105. (Pubitemid 38328741)
25. Winder FG. 1964. The antimicrobial action of streptomycin, isoniazid and PAS. Butterworth, London, United Kingdom.